CNMD (CONMED Corporation)
Insider Trading Activity
Every open-market purchase and sale reported by CNMD officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-17 | John E Gallagher | Executive Vice President & CFO | A | — | — |
| 2026-07-02 | Celine Christine Martin | Director | A | — | — |
| 2026-07-02 | Jeffrey B. Mirviss | Director | A | — | — |
| 2026-06-03 | David M. Bronson | Director | M | — | — |
| 2026-06-03 | LaVerne H Council | Director | M | — | — |
| 2026-06-03 | Charles Farkas | Director | M | — | — |
| 2026-06-03 | Mark Kaye | Director | M | — | — |
| 2026-06-03 | Kim Kelderman | Director | A | — | — |
| 2026-06-03 | Barbara J Schwarzentraub | Director | M | — | — |
| 2026-04-02 | Pat Beyer | President & CEO | A | — | — |
| 2026-03-18 | PETER K SHAGORY | EVP, STRAT & CORP DEVT | A | — | — |
| 2026-03-18 | Hollie K Foust | General Counsel & Corp Sec | A | — | — |
| 2026-03-18 | Matthew Schabacker | VP GM Advanced Surgical | A | — | — |
| 2026-03-18 | Brent Lalomia | Executive VP RA, QA | A | — | — |
| 2026-03-18 | John D. Ferrell | Executive Vice President - HR | A | — | — |
| 2026-03-10 | Brent Lalomia | Executive VP RA, QA | MIXED | — | — |
| 2026-03-04 | Pat Beyer | President & CEO | A | — | — |
| 2026-03-04 | PETER K SHAGORY | EVP, STRAT & CORP DEVT | A | — | — |
| 2026-03-04 | John D. Ferrell | Executive Vice President - HR | A | — | — |
| 2026-03-04 | Matthew Schabacker | VP GM Advanced Surgical | A | — | — |
| 2026-03-04 | Johonna Marie Pelletier | Treasurer and VP, Tax | A | — | — |
| 2026-03-04 | Andrew James Moller | VP Corporate Controller | A | — | — |
| 2026-03-04 | Brent Lalomia | Executive VP RA, QA | A | — | — |
| 2026-03-04 | Hollie K Foust | General Counsel & Corp Sec | A | — | — |
| 2026-02-26 | Mark Kaye | Director | M | — | — |
| 2025-11-24 | Richard Glaze | Chief Information Officer | Sell | — | — |
| 2025-11-21 | Richard Glaze | Chief Information Officer | MIXED | — | — |
| 2025-11-07 | Todd W Garner | Executive Vice President & CFO | Sell | — | — |
| 2025-11-05 | Hollie K Foust | General Counsel & Corp Sec | MIXED | — | — |
| 2025-11-03 | Todd W Garner | Executive Vice President & CFO | MIXED | — | — |
| 2025-09-15 | Charles Farkas | Director | Sell | — | — |
| 2025-09-09 | Kim Kelderman | Director | A | — | — |
| 2025-08-08 | Todd W Garner | Executive Vice President & CFO | Sell | — | — |
| 2025-06-04 | David M. Bronson | Director | M | — | — |
| 2025-06-04 | LaVerne H Council | Director | M | — | — |
| 2025-06-04 | Charles Farkas | Director | M | — | — |
| 2025-06-04 | Mark Kaye | Director | A | — | — |
| 2025-06-04 | Brian Concannon | Director | M | — | — |
| 2025-06-04 | Barbara J Schwarzentraub | Director | M | — | — |
| 2025-06-04 | Martha Goldberg Aronson | Director | M | — | — |
| 2025-05-30 | Charles Farkas | Director | MIXED | — | — |
| 2025-05-21 | John L Workman | Director | M | — | — |
| 2025-05-15 | Stephan Epinette | VP GM International | A | — | — |
| 2025-05-06 | Charles Farkas | Director | Sell | — | — |
| 2025-05-01 | Matthew Schabacker | VP GM Advanced Surgical | A | — | — |
| 2025-04-08 | Todd W Garner | Executive Vice President & CFO | A | — | — |
| 2025-03-17 | PETER K SHAGORY | EVP, STRAT & CORP DEVT | MIXED | — | — |
| 2025-03-11 | Brent Lalomia | Vice President QA and RA | MIXED | — | — |
| 2025-03-05 | Todd W Garner | Executive Vice President & CFO | A | — | — |
| 2025-03-05 | PETER K SHAGORY | EVP, STRAT & CORP DEVT | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Former President & CEO | 256,925 | — |
| — | President and CEO | 93,496 | — |
| — | Director | 92,139 | — |
| — | EVP, Finance, CFO | 55,685 | — |
| — | VICE PRESIDENT | 45,275 | — |
| — | Director | 45,222 | — |
| — | EVP & Chief HR & Legal Officer | 37,692 | — |
| — | Director | 20,891 | — |
| — | EVP, Commercial Operations | 19,122 | — |
| — | Director | 17,909 | — |
| — | EVP Mfg. Ops & Business System | 15,933 | — |
| — | Director | 15,527 | — |
| — | EVP-Corporate QA/RA | 15,465 | — |
| — | Treasurer and VP, Tax | 15,434 | — |
| — | Group Executive Vice President | 14,947 | — |
| — | Director | 14,391 | — |
| — | Special Counsel & Corp Secy | 13,912 | — |
| — | VICE PRESIDENT | 12,430 | — |
| — | VP-Corporate Controller | 11,504 | — |
| — | President & CEO | 10,807 | — |
| — | Director | 10,396 | — |
| — | Director | 10,116 | — |
| — | Director | 9,949 | — |
| — | Director | 7,400 | — |
| — | Director | 6,454 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the CNMD quote page; the site-wide leaderboard is on the insider transactions hub.